Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods

Cancer Epidemiology
Arnaud SeigneurinMarc Colonna

Abstract

Estimating overdiagnosis associated with breast cancer screening may use annual incidence rates of cancer. We simulated populations invited to screening programmes to assess two lead-time adjustment methods. Overdiagnosis estimates were computed using the compensatory drop method, which considered the decrease in incidence of cancers among older age groups no longer offered screening, and the method based on the decrease in incidence of late-stage cancers. The true value of overdiagnosis was 0% in all the data sets simulated. The compensatory drop method yielded an overdiagnosis estimate of -0.1% (95% credibility interval -0.5% to 0.5%) when participation rates among the population and risk of cancers were constant. However, if participation rates increased with calendar year as well as risk of cancer with birth cohorts, the overdiagnosis estimated was 11.0% (10.5-11.6%). Using the method based on the incidence of early- and late-stage cancers, overdiagnosis estimates were 8.9% (8.5-9.3%) and 17.6% (17.4-17.9%) when participation rates and risks of cancer were constant or increased with time, respectively. Adjustment for lead time based on the compensatory drop method is accurate only when participation rates and risks of cance...Continue Reading

References

Sep 15, 2005·Journal of Medical Screening·Stephen W Duffy
Jul 11, 2009·BMJ : British Medical Journal·Karsten Juhl Jørgensen, Peter C Gøtzsche
Nov 3, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Donella PulitiEugenio Paci
Nov 7, 2009·Cancer Causes & Control : CCC·Stephen MorrellBruce Armstrong
Oct 13, 2010·Journal of the National Cancer Institute·Donald E HensonArnold M Schwartz
Nov 8, 2012·Journal of Medical Screening·Donella PulitiUNKNOWN EUROSCREEN Working Group
Nov 23, 2012·The New England Journal of Medicine·Archie Bleyer, H Gilbert Welch
May 18, 2013·Breast Cancer Research : BCR·Stephen W Duffy, Dharmishta Parmar

❮ Previous
Next ❯

Citations

Jul 15, 2015·Expert Review of Anticancer Therapy·Silvia Martina FerrariPoupak Fallahi
May 31, 2016·The Breast : Official Journal of the European Society of Mastology·Arnaud SeigneurinMarc Colonna
Nov 7, 2016·Mayo Clinic Proceedings·L Rachid SalmiSimone Mathoulin-Pélissier
Nov 9, 2017·Journal of the National Cancer Institute·Theodora M RippingMireille J M Broeders

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.